DIOMEGA + Stress Sommeil
Food supplement declared in France, declaration No 2017-4-57, decision dated 4 April 2017
DIOMEGA + Stress Sommeil, from Laboratoire Dioter, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Pantothenic acid (vitamin B5), Biotin (vitamin B8), Folate (vitamin B9), Magnesium, Nicotinamide (vitamin B3). 1 point in its composition requires a check (prohibited substance, dose or novel food).
- Brand
- not provided
- Food business operator placing the product on the market
- Laboratoire Dioter
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 1 gélule
- Directions for use
- Prendre une gélule par jour, le soir avec un verre d'eau.
- Objectives stated by the manufacturer (these are not authorised claims)
- Sleep
Declaration 203161, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Other active ingredients
| Name | Per day |
|---|---|
| Huile de poisson | not declared |
| Mélatonine | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pteroylmonoglutamic acid | Folate (vitamin B9) | 1,000 µg | 200 µg |
| magnesium oxide | Magnesium | 250 mg | 300 mg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| thiamin mononitrate | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| cyanocobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
Additives
E306, E392, E471, E171, E141
Other ingredients
huile de soja, Gélatine de poisson
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Regulatory points
- À vérifier
The composition lists additive E171 (titanium dioxide), removed from the list of additives allowed in food, supplements included: since 7 August 2022, a supplement containing it can no longer be placed on the market in the Union. The declaration predates this removal: if the product is still sold, its formula must have changed; check the label.
Source: Regulation (EU) 2022/63: titanium dioxide (E171) removed from the food additives allowed in the EU, règlement (UE) 2022/63.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Huile de poisson
Read the warning, when it applies and the studies cited
FISH OIL
Route of administration: Oral
Cautions and warnings
Condition of application: Pain of rheumatoid arthritis.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
Condition of application: Healthy mood balance.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression.
- Mélatonine
Read the warning, when it applies and the studies cited
MELATONIN - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993).
Sources cited by Health Canada (5)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. British Journal of Clinical Pharmacology 2000;49:423-427. PubMed Randomised trial
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Review article
- Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, von Känel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. Journal of Pineal Research 2008;44:127-133. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993).
Sources cited by Health Canada (12)
- Arangino S, Cagnacci A, Angiolucci M, Vacca AMB, Longu G, Volpe A, Melis GB. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. American Journal of Cardiology 1999; 83(9):1417-1419. PubMed Randomised trial
- Cagnacci A, Arangino S, Renzi A, Paoletti AM, Melis GB, Cagnacci P, Volpe A. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clinical Endocrinology (Oxford) 2001a;54(3):339-346. PubMed Randomised trial
- Calvo JR, Guerrero JM, Osuna C, Molinero P, Carrillo-Vico A. Melatonin triggers Crohn's disease symptoms. Journal of Pineal Research 2002;32(4):277-278. PubMed Case report
- Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005;27:189-200. PubMed Review article
- der Marderosian A, Beutler JA, editors. 2003. The Review of Natural Health Products, 3rd edition. St. Louis (MO): Facts and Comparisons®, a Wolters Kluwer Company.
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Review article
- Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best practice & research. Clinical endocrinology & metabolism 2010;24(5):829-841. PubMed Review article
- Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998;351:1254. PubMed
- Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. American Journal of respiratory and critical care medicine 2002;166:1055-1061. PubMed
- Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. Journal of Allergy and Clinical Immunology 2003;112(3):513-517. PubMed
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002; Holliman and Chyka 1997).
Sources cited by Health Canada (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b).
Sources cited by Health Canada (2)
- Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Annals of Medicine 1998;30(1):122-130. PubMed Review article
- Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, Friedrich-Koch A, Steffen R. Impact of melatonin on driving performance. Journal of Travel Medicine 1998b;5(1):7-13. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002).
Sources cited by Health Canada (3)
- Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T 2004. Melatonin for treatment of sleep disorders. Evidence Report/Technology Assessment No. 108. AHRQ Publication No. 05-E002-2. Rockville (MD): U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. November, 2004.
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach. 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002.
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Contraindications
Do not use if you are pregnant or breastfeeding (IOM 2004).
Sources cited by Health Canada (1)
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Known adverse reactions
Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002).
Sources cited by Health Canada (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
Health Canada monograph dated 19 December 2025
MELATONIN - Sublingual
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993).
Sources cited by Health Canada (5)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. British Journal of Clinical Pharmacology 2000;49:423427. PubMed Randomised trial
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Review article
- Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, von Känel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. Journal of Pineal Research 2008;44:127-133. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993).
Sources cited by Health Canada (12)
- Cagnacci A, Arangino S, Renzi A, Paoletti AM, Melis GB, Cagnacci P, Volpe A. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clinical Endocrinology (Oxford) 2001a;54(3):339-346. PubMed Randomised trial
- Calvo JR, Guerrero JM, Osuna C, Molinero P, Carrillo-Vico A. Melatonin triggers Crohn's disease symptoms. Journal of Pineal Research 2002;32(4):277-278. PubMed Case report
- Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005;27:189-200. PubMed Review article
- der Marderosian A, Beutters JA, editors. 2003. The Review of Natural Health Products, 3rd edition. St. Louis (MO): Facts and Comparisons®, a Wolters Kluwer Company.
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
- Maestroni GJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993;14(1):1-10. PubMed Review article
- Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best practice & research. Clinical endocrinology & metabolism 2010;24(5):829-841. PubMed Review article
- Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998;351:1254. PubMed
- Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. American Journal of respiratory and critical care medicine 2002;166:1055-1061. PubMed
- Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. Journal of Allergy and Clinical Immunology 2003;112(3):513517.
- Arangino S, Cagnacci A, Angiolucci M, Vacca AMB, Longu G, Volpe A, Melis GB. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. American Journal of Cardiology 1999;83(9):1417-1419. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002; Holliman and Chyka 1997).
Sources cited by Health Canada (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b).
Sources cited by Health Canada (2)
- Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Annals of Medicine 1998;30(1):122-130. PubMed Review article
- Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, Friedrich-Koch A, Steffen R. Impact of melatonin on driving performance. Journal of Travel Medicine 1998b;5(1):7-13. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002).
Sources cited by Health Canada (3)
- Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T. Melatonin for treatment of sleep disorders. Evidence Report/Technology Assessment No. 108. AHRQ Publication No. 05-E002-2. Rockville (MD): U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. November, 2004.
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach. 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002.
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Contraindications
Do not use if you are pregnant or breastfeeding (IOM 2004).
Sources cited by Health Canada (1)
- IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71.
Known adverse reactions
Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002).
Sources cited by Health Canada (1)
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews Issue 2 2002. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf DOI
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “DIOMEGA + Stress Sommeil: composition and regulation”, https://compoatlas.com/en/supplements/products/203161-diomega-stress-sommeil, updated 15 November 2026.